Hilary Marston, M.D., M.P.H. Chief Medical Officer (CMO) of the FDA | Official Website
Hilary Marston, M.D., M.P.H. Chief Medical Officer (CMO) of the FDA | Official Website
This is a 20% increase over the number of companies cited in the previous year.
Of the 36 citations issued, the most common citations include:
- Document control procedures have not been adequately established.
- Procedures to ensure that all purchased or otherwise received product and services conform to specified requirements have not been adequately established.
- Procedures for corrective and preventive action have not been adequately established.
Most of the companies cited were involved in either Biologics or Devices sectors.
All of the companies cited should take voluntary actions to correct their managing operations.
The FDA routinely inspects facilities across the nation to determine if the workplace and their products are compliant with FDA-regulated laws and regulations implemented to improve overall public health. Inspection results are then disclosed publicly.
The FDA is a government agency that is primarily responsible for monitoring the production and distribution of human and animal drugs, biological products, medical supplies and tobacco products for safety quality, according to its website.
Company Name | Area of Business | Inspection Date | Issue Cited |
---|---|---|---|
Italian Products USA, Inc. | Food and Cosmetics | 06/28/2023 | Hazard analysis biological, chemical, physical |
Italian Products USA, Inc. | Food and Cosmetics | 06/28/2023 | Evaluation - performance, risk |
Italian Products USA, Inc. | Food and Cosmetics | 06/28/2023 | Verification activity frequency |
Italian Products USA, Inc. | Food and Cosmetics | 06/28/2023 | Record - translate to English |
Janssen Pharmaceuticals, Inc. | Biologics | 12/14/2023 | Training , Education , Experience overall |
Janssen Pharmaceuticals, Inc. | Biologics | 12/14/2023 | Cleaning / Sanitizing / Maintenance |
Janssen Pharmaceuticals, Inc. | Biologics | 12/14/2023 | Scientifically sound laboratory controls |
Janssen Pharmaceuticals, Inc. | Biologics | 12/14/2023 | Who must report - manufacturer |
Light Age, Inc. | Devices | 09/29/2023 | Lack of or inadequate organizational structure |
Light Age, Inc. | Devices | 09/29/2023 | Management review - defined interval, sufficient frequency |
Light Age, Inc. | Devices | 09/29/2023 | Training - Lack of or inadequate procedures |
Light Age, Inc. | Devices | 09/29/2023 | Design history file |
Light Age, Inc. | Devices | 09/29/2023 | Procedures not adequately established or maintained |
Light Age, Inc. | Devices | 09/29/2023 | Purchasing controls, Lack of or inadequate procedures |
Light Age, Inc. | Devices | 09/29/2023 | Evaluation of suppliers, contractors, etc., requirements |
Light Age, Inc. | Devices | 09/29/2023 | Calibration procedures - content |
Light Age, Inc. | Devices | 09/29/2023 | Remedial action |
Light Age, Inc. | Devices | 09/29/2023 | Nonconforming product, Lack of or inadequate procedures |
Light Age, Inc. | Devices | 09/29/2023 | Lack of or inadequate procedures |
Light Age, Inc. | Devices | 09/29/2023 | DMR - not or inadequately maintained |
Light Age, Inc. | Devices | 09/29/2023 | DHR - not or inadequately maintained |
Light Age, Inc. | Devices | 09/29/2023 | Complaints |
Manara, Dr Louis R | Biologics | 05/23/2023 | Donors with risks not determined ineligible |
Micro Stamping Corporation | Devices | 01/18/2023 | Procedures not adequately established or maintained |
Micro Stamping Corporation | Devices | 01/18/2023 | Purchasing controls, Lack of or inadequate procedures |
Micro Stamping Corporation | Devices | 01/18/2023 | Environmental control Lack of or inadequate procedures |
Micro Stamping Corporation | Devices | 01/18/2023 | Product rework procedures, Lack of or inadequate procedures |
Micro Stamping Corporation | Devices | 01/18/2023 | Lack of or inadequate procedures |
SOFIE Company | Drugs | 01/20/2023 | Determination need for investigation |
SOFIE Company | Drugs | 01/20/2023 | Written QA procedures established, followed |
SOFIE Company | Drugs | 01/20/2023 | Equipment procedures |
SOFIE Company | Drugs | 01/20/2023 | Adequate controls (general) |
SOFIE Company | Drugs | 01/20/2023 | Equipment |
SOFIE Company | Drugs | 01/20/2023 | Before implementing new procedure establish and document accuracy etc. |
SOFIE Company | Drugs | 01/20/2023 | Correction of problems |
SOFIE Company | Drugs | 01/20/2023 | Written complaint procedures |